Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.80 |
| ▸ | CNR2 | P34972 | 3/20 | 0.80 |
| ▸ | PRKCA | P17252 | 3/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | FAAH | O00519 | 3/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7192929 | 1.00 | CNR1 (0.80) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL7192934 | 1.00 | CNR1 (0.80) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL3495835 | 1.00 | CNR1 (0.80) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL10492090 | 1.00 | CNR1 (0.80) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL10492106 | 0.96 | CNR1 (0.75) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL10492119 | 0.96 | PRKCA (0.76) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL1145290 | 0.96 | PRKCA (0.76) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL7557200 | 0.96 | PRKCA (0.76) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL7557194 | 0.96 | PRKCA (0.76) | CNR1CNR2PRKCAPRKCEPRKCQ | |
| SCHEMBL29644755 | 0.96 | PRKCA (0.76) | CNR1CNR2PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20180282762-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | EDITAS MEDICINE, INC. | 2018-10-04 | — | — | US | disclosed |
| US-7294496-B1 | Cloned human lysophospholipase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126434-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | ZFX, DCLRE1B, APOBEC3C | CNR1 4229/4885CNR2 4464/4885PRKCA 1201/4885 |
| US-20180282762-A1 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | ZFX, DCLRE1B, APOBEC3C | CNR1 4229/4885CNR2 4464/4885PRKCA 1201/4885 |
| US-11390884-B2 | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells | ZFX, DCLRE1B, APOBEC3C | CNR1 4229/4885CNR2 4464/4885PRKCA 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.